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 Kidney transplant prevalence and costs have been increasing steadily in the past few 
decades and this trend is anticipated to continue for years to come.  Patient outcomes are 
heavily influenced by the amount of time they are waiting for a transplant and by the quality of 
care they are receiving up to the transplant.  This paper intends to increase positive patient 
outcomes and decrease costs by identifying potential kidney transplant patients earlier than 
traditional methods.   I use medical claims data to determine common risk factors of all patients 
who have received a kidney transplant.  For the control group I include all patients who have 
not received a kidney transplant.  I used a binary logistic regression utilizing common risk 
factors determined by the claims data to determine what factors are significant and which ones 
have a larger impact on predicting kidney transplantation.  This approach attempts to predict 
patient health outcomes using claims data instead of clinical data which is often used in other 
research methods.   
The results of my analysis were that the risk factors found in clinical research of kidney 
transplantation were the same risk factors found using medical claims data.   I determined 
diabetes, hypertension and end stage renal disease were strong indicators of potential kidney 
transplantation using claims data alone.  My conclusion is that medical claims data can be used 
in place of clinical data when clinical data is not available or does not exist.  




Kidney transplantation is a life changing procedure that is expensive and has the 
potential for serious complications.  To increase the patient’s survival time after a kidney 
transplant it is important to intervene with the patient early on in the diagnosis to ensure 
proper treatment is given leading up to the transplant.  This intervention will likely lead to the 
best outcome for the patient and help reduce any unnecessary procedures.  It will also reduce 
costs because much of the costs associated with kidney transplant can occur before the 
transplant actually takes place.  According to (Laupacis, 1996) the expenses associated with pre-
transplant costs such as dialysis can cost more than the transplant itself and the quality of life of 
the patient decreases the longer the patient is on dialysis (Meier-Kriesche, 2002).  These 
expenses can range from $7,000 for home dialysis to over $24,000 or more for annual dialysis 
costs (Hoffstein, 1976).  These costs are higher today although the disparity between treatment 
options remains.  This is why it is important to intervene with the patient early and ensure they 
are getting care from quality and cost effective providers.   
Not only have costs been increasing but kidney transplant prevalence has also been 
increasing.  As shown in the chart below (Figure 1) the annual number of kidney transplants has 
been increasing steadily since 1988 when there were fewer than 10,000 transplants per year to 
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2009 when there were almost 18,000 transplants.  This trend will continue as long as long as 
kidney transplantation is the only option for those with end stage renal disease.   
 
Figure 1: Annual Number of Kidney Transplants From 1988 to 2009 
 
Even if all the proper steps are taken to ensure the patient is receiving the best care 
given by the highest quality clinics there is still a shortage of kidneys available for 
transplantation.  Because of this, some patients can be on the kidney transplant waiting list for 
years waiting for a matching donor kidney.  By intervening early in the diagnosis it is possible to 
inform the patient of their best and most cost effective treatment options early and get them 
on the waiting list at the earliest possible time.  Even a simple thing like having the patient on 
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home dialysis can save thousands of dollars and possibly lead to better health outcomes for the 
patient.     
 Health care costs have been rising steadily for many years and a part of this increase is 
due to inefficient or unnecessary care.  By steering patients to high quality and low cost 
providers it is possible to increase the likelihood of successful treatments and eliminate 
unnecessary expenses for the patient.  High quality providers are more likely to reduce overall 
costs by eliminating unnecessary procedures and increasing their patient’s health to prevent 
more doctor visits in the future.  Kidney transplantation is just a small part of total healthcare 
costs but this is one area where it is possible to intervene in care and help reduce costs and 
increase health outcomes if the potential for kidney transplantation is identified early.   
 Using claims data in place of clinical data can benefit researches in many ways and has 
the potential increase the identification of various diseases.  The use of claims data can help 
eliminate selection bias that often occurs in research using clinical data.  For example, in my 
research I am making no decisions on whom to include or exclude from my data set.  Any claim 
contained in the CMS data set is included and there is no other selection criterion on what data 
should be excluded from the data set.  This differs from many clinical studies where the 
researcher has to choose which members to include and this selection can introduce selection 
bias whether it is intentional or not.  As stated earlier, the claims data for this analysis is 
Medicare claims data obtained from the Center for Medicare & Medicaid Services (CMS).  The 
claims I used include hospital and physician claims starting at the transplant date and going 
backwards to the earliest claims available.  For the study group I identified all patients who 
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have received a kidney transplant in the past and looked for specific diagnosis codes, procedure 
codes, and any other variables that could be important in predicting kidney failure.  After 
identifying all patients that have received a transplant, I compiled my control group which 
consisted of all other patients in the data that did not receive a kidney transplant.  For the 
group who has not received a transplant I will look at all claims data available regardless of 
when the claim occurred.  What I attempted to determine are the earliest indicators of 
potential kidney failure which in turn lead to kidney transplantation.   













There has been a wide range of research done on the topic of what risk factors lead to end 
stage renal disease and kidney transplantation.  The research varies from topics focused on what 
clinical risk factors are associated with kidney failure to what behaviors may contribute or 
complicate existing kidney diseases.  However, there has not been much research done on 
whether claims data alone can be used to predict kidney failure, as I am doing for this analysis.   
 A study done by Hsu (2009) researched 177,570 individuals in a northern California health 
system who agreed to participate in annual checkups for a ten year period.  The study started in 
1964 and followed these individuals in the US Renal Data System registry through the year 2000.  
Hsu found a total of 842 cases of end stage renal disease out of the initial 177,570 participating in 
the study; which is .47% of the total population.  Of these 842 participants who were identified as 
having end stage renal disease, there were many potential risk factors discovered.  These risk 
factors align with what was found in other studies as well and helps to confirm that these factors 
can contribute to decreased kidney function.  Hsu also mentions some “novel” risk factors such as 
smoking, which was also included in some of the models he analyzed.  Hsu used five different 
models, each with different risk factors.  The final model used in the study was a multivariate 
model which includes the established risk factors as well as some the novel risk factors.  Significant 
risk factors Hsu discovered were sex, old age, proteinuria, diabetes, low educational attainment, 
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race, high blood pressure, body mass index, and serum creatinine level.  Hsu found that the two 
most important risk factors are proteinuria and excess weight.   
Perry (1995) performed a similar study but only included hypertensive veterans as 
subjects.  The goal of his study was to determine whether or not there is a relationship between 
high blood pressure and end stage renal disease.  This study included 5730 black and 6182 white 
male veterans identified through the Veterans Hypertension Screening and Treatment Program 
Clinics.  After a 13.9 year follow up, 5337 of the patients died and 245 developed end stage renal 
disease.  Perry used a proportional hazards modeling to fit multivariate survival models in order to 
determine if there is an effect on end stage renal disease with treatment for high blood pressure.  
Important risk factors observed in this study were being black or diabetic which could more than 
double the odds of the patient developing end stage kidney disease.  Having a history of urinary 
tract problems or having high pretreatment SBP are also important risk factors of developing end 
stage renal disease according to this study.    
 Diabetes is considered one of the major risk factors associated with end stage renal disease 
and there are many studies looking at this relationship.  Ritz (1999) found that with the increase in 
type II diabetes there has also been an increase in end stage renal disease; particularly in countries 
with a western lifestyle.  Ritz hypothesized that end stage renal disease was developed due to 
subjects with hypertension living longer than they had in the past.  With the advances in 
treatment for hypertension it’s possible to live longer lives but other complications of 
hypertension also have more time to develop.   
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Diabetes is one of the most common risk factors in developing end stage renal disease but 
it can affect different races in different ways.  Cowie (1989) conducted a study looking at the 
difference between black and white diabetics and how they differ in developing end stage renal 
disease.  Cowie concluded black men were 2.6 times more likely to develop end stage renal 
disease than their white counterparts.  This added variable can further complicate studying the 
causes of kidney failure especially when demographic information is not available.   
In addition to these cohort studies, clinical and demographic data is often used to study 
end stage renal disease risk factors.  Most often both types of data are used as in the study done 
by Tangri (2011).  This study used Cox proportional hazards regression methods to determine 
significant risk factors of end stage renal disease.  The results of the study determined the most 
accurate model included age, sex, estimated GFR, albuminuria, serum calcium, serum phosphate, 
serum bicarbonate, and serum ablumium.   Tangri concluded that the model created in this study 
can be used to successfully predict kidney failure in patients with stage 3 to stage 5 chronic kidney 










The data I am using comes from the Centers for Medicare & Medicaid Services (CMS).  
Specifically, the data is Medicare claims data from 2008-2010 which includes member data, 
inpatient claims, outpatient claims, pharmacy claims, and provider claims.  In total, there will be 
approximately 220 million claims analyzed.  I chose to use this data source because it is 
provided for public use and has no identifying information on the claim so all the claims data 
remains completely confidential.  My main analysis will focus on diagnosis codes and other 
information provided on a medical claims which makes this data a very reasonable and reliable 
source for my analysis.  In addition, since this data is Medicare data the claims will be coming 
from an older population and these are the people who will normally be receiving kidney 
transplants.   
 The quality of the data is very good; however, there can be some inconsistencies in the 
data caused primarily by human error.  In some cases claims are coded incorrectly by the 
providers and this data is then passed on to the claims adjudication system.  When this happens 
the member may have incorrect diagnosis or procedure codes listed on their claims which will 
affect how the member is flagged for specific disease diagnosis.  When a claim is coded 
incorrectly, the error is usually caught by either the insurance company processing the claim or 
the provider; however, it may take time to reprocess the correct claim so there still may be 
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errors in the data.  Another issue with the quality of the data is that patients can move and 
switch health plans so the data may not follow the patient to their new health plan.  Using CMS 
data this issue should not be too much of an issue, but it is something consider when analyzing 
claims data.     
The first step in my analysis is to identify all the patients who have received a kidney 
transplant.  To identify those with a kidney transplant I looked for a diagnosis code of V420 and 
flagged those members as “received a kidney transplant”.   Then, I looked at all of these 
member’s claims up to the kidney transplant date.   I only wanted to look at claims data before 
the transplant date since I am looking for risk factors leading to a kidney transplant, not factors 
after a transplant takes place.   
I chose to run a binary logistic regression to complete my analysis.  I chose this type of 
analysis for many different reasons.  First of all, there is no linear relationship with my 
independent variables and dependent variable so I was unable to perform an OLS regression.  
Secondly, my goal in this analysis is to predict the likelihood of a patient in receiving a kidney 
transplant.   The maximum likelihood estimation associated with the binary logistic regression 
makes analyzing each independent variables influence on the dependent variable relatively 
easy by looking at each variables corresponding odds ratio.  Also, my use of dummy variables 
makes a binary logistic regression a very good choice.  Because diagnosis codes are not 
continuous variables, I converted all of my diagnosis codes into dummy variables for each 
specific diagnosis.  The initial list of risk variables along with the name of the corresponding 
dummy variable is listed in the below table (Table 1).  For example, in the case of the end stage 
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renal disease diagnosis of 5856 a dummy variable was created called “End Stage Renal Disease” 
and the field was marked with a 1 if the patient had this diagnosis and marked with a 0 is there 
was no history of this diagnosis.  This was done in a similar manner for all other diagnosis codes 
as well as with the other risk factors I initially looked at.  In the below table the % indicates a 
wild card.   Some diagnosis codes and prescription drug NDC codes have more than one code 
indicating the same drug or diagnosis.   
Table 1: Risk Factors and Dummy Variable Names 
Risk Factor CPT Code Risk Factor NDC  
PROTEIN URINE TEST PROCEDURE 
CODE 
84155, 82570, 84156 CALCITROL RX 000930657%% 
Risk Factor Demographic Variable CALCIUM ACETATE RX 000540088%% 
AGE 50-59 Age 50-59 FUROSEMIDE RX 0037802%%%% 
AGE 40-49 Age 40-49 ALLOPURINOL RX 003780137%% 
MALE Male INSULIN RX 000882220%% 
Risk Factor TIN LIPITOR RX 00071015%%% 
FAIRVIEW 410991680 NORVASC RX 000691540%% 
HENNEPIN 411461900 PHOSLO RX 492300640%% 
HEALTHSPAN 363261413 RENAGEL RX 584680021%% 
KIDNEY SPECIALISTS 411356741 RENAL CAPS RX 602580162%% 
Risk Factor Therapy Class Code Risk Factor ICD Code 
DIHYDROPYRIDINES THERAPY CLASS RX 242808 
END STAGE RENAL DISEASE 
DIAGNOSIS 
5856 
HMG-COA REDUCTASE INHIBITORS 
THERAPY CLASS RX 
240608 
UNSPECIFIED DISORDER OF 
KIDNEY AND URETER 
DIAGNOSIS 
5939 
ADRENALS THERAPY CLASS RX 680400 
CHRONIC KIDNEY DISEASE 
DIAGNOSIS 
585% 
BETA-ADRENERGIC BLOCKING AGENTS 
THERAPY CLASS RX 
242400 DIABETES DIAGNOSIS 250% 
INSULINS THERAPY CLASS RX 682008 HYPERTENSION DIAGNOSIS 403% 
LOOP DIURETICS THERAPY CLASS RX 402808 DIALYSIS COMPLICATIONS 99673 
OPIATE AGONISTS THERAPY CLASS RX 280808     
ANGIOTENSIN-CONVERTING ENZYME 
INHIBITORS THERAPY CLASS RX 
243204     
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The initial list of diagnosis and procedure codes is quite extensive and would have been 
too lengthy to include in my final model.  In order to minimize the risk factors and make the 
analysis more feasible, I started by looking at what risk factors were insignificant and could be 
safely removed from my analysis.  My analysis started with a lengthy list of variables, shown 
below (Table 2), along with their corresponding point estimates and significance test scores 
derived from my binary logistic regression.  There were a variety of variables which I expected 
to be significant that were actually shown as being insignificant along with point estimates that 
did not seem logical.  As you can see from the below list, the vast majority of the variables are 
not significant and the ones that I would expect to be significant have a negative point estimate 
which goes against all previous research on which variables lead to kidney transplantation.   
 
Table 2. Initial Regression Results 





END STAGE RENAL DISEASE 1 0.26612 0.15516 2.9417 0.0863 
UNSPECIFIED DISORDER OF THE 
KIDNEY 
1 -0.50499 0.1426 12.5405 0.0004 
RELEASE_URETHRAL_STR 1 -0.42647 0.20483 4.3349 0.0373 
CHRONIC KIDNEY DISEASE 1 -0.10038 0.16433 0.3731 0.5413 
CORONARY ATHEROSCLEROSIS 1 -0.10426 0.18971 0.302 0.5826 
RENAL DIALYSIS COMPLICATIONS 1 -0.11067 0.16213 0.466 0.4949 
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Table 2. cont. 
HYPERTENSION CHRONIC KIDNEY 
DISEASE 
1 -0.01991 0.16342 0.0148 0.9031 
PROTEIN URINE TEST 1 -0.15487 0.16018 0.9347 0.3336 
MALE 1 0.19827 0.13008 2.3232 0.1275 
AGE 1 0.05588 0.0127 19.3531 <.0001 
TEENS 1 -0.06272 0.50865 0.0152 0.9019 
TWENTIES 1 -0.77517 0.54504 2.0227 0.155 
THIRTIES 1 -0.0465 0.58715 0.0063 0.9369 
FORTIES 1 0.74627 0.66193 1.2711 0.2596 
FIFTIES 1 1.12802 0.72863 2.3967 0.1216 
SIXTIES 1 1.56352 0.83135 3.537 0.06 
SEVENTY PLUS 1 2.04738 0.96325 4.5178 0.0335 
CALCITRIOL 1 -0.06948 0.15151 0.2103 0.6465 
INSULIN 1 0.31487 0.23441 1.8043 0.1792 
RENAL_CAP 1 -0.15797 0.15339 1.0605 0.3031 
LIPITOR 1 -0.35738 0.15627 5.2298 0.0222 
CALCIUM_ACETATE 1 -0.12243 0.14944 0.6712 0.4126 
NORVASC 1 -0.31119 0.1976 2.4802 0.1153 
FUROSEMIDE 1 0.09149 0.16412 0.3108 0.5772 
RENAGAL 1 0.05533 0.16896 0.1072 0.7433 
ALLOPURINOL 1 -0.52829 0.23121 5.2209 0.0223 
PHOSLO 1 0.16335 0.16535 0.9761 0.3232 
BETA_ADRENERGIC 1 -0.12222 0.1509 0.656 0.418 
OPIATE_AGONISTS 1 -0.57826 0.13781 17.6067 <.0001 
HMG_COA_REDUCTASE 1 -0.14777 0.15293 0.9337 0.3339 
DIHYDROPYRIDINES 1 -0.20104 0.13186 2.3245 0.1274 
ANGIOTENSIN_CONVERTI 1 -0.15115 0.12974 1.3573 0.244 
INSULIN_THER 1 0.16651 0.22029 0.5714 0.4497 
LOOP_DIURETICS 1 -0.05367 0.14544 0.1362 0.7121 
ADRENALS 1 -0.20834 0.1244 2.8047 0.094 
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Since all of my variables are describing a very specific population and because all of 
them are dummy variables there is a very good chance there is multicollinearity in my initial 
model.  To correct for this I removed many of the variables that were correlated with each 
other.  For instance, the drug Norvasc is used to treat hypertension so if the patient is 
diagnosed with hypertension chances are they are also taking Norvasc.   This issue occurred for 
all of the prescription drugs I initially included in my model so I decided it would be best to 
remove all drugs from my regression and simply focus on the disease diagnosis codes.  Because 
I am solely focusing on diagnosis code data, I also removed the age variables and procedure 
code variables from the model.  I did this because I wanted to limit any other variables affecting 
the outcome of my disease diagnosis variables.  I determined that a person’s age could be 
correlated with hypertension and diabetes and I wanted to limit the multicollinearity the best 
that I could.  The below table (Table 3) shows my final model along with point estimates and 
confidence intervals for all of the included variables in the model.  These variables included in 
the final model were all significant at the 95% level and each appeared to contribute to a 
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Table 3: Final Model/Model Fit Statistics 







END STAGE RENAL DISEASE 1.854 1.612 2.133 
UNSPECIFIED DISORDER OF THE KIDNEY 1.356 1.137 1.618 
CHRONIC KIDNEY DISEASE 1.642 1.438 1.877 
CORONARY ATHEROSCLEROSIS 1.23 1.03 1.43 
RENAL DIALYSIS COMPLICATIONS 1.12 0.950 1.290 
DIABETES 1.29 1.05 1.53 
HYPERTENSION CHRONIC KIDNEY DISEASE 1.092 0.966 1.235 






Covariates   
AIC 2665.691 1488.122   
SC 2674.03 1554.835   
-2 Log L 2663.691 1472.122   
Testing Global Null Hypothesis: BETA=0 
Test Chi-Square DF Pr > ChiSq 
Likelihood Ratio 1191.569 7 <.0001 
Score 4328.2922 7 <.0001 
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CHAPTER IV: 
RESULTS AND INTERPRETATION 
 The results of the model shows similar results to what has been found in previous research 
of what risk factors can lead to kidney failure.  Past research has shown that hypertension, 
diabetes, end stage renal disease, and coronary atherosclerosis are all leading indicators of 
potential kidney transplantation.  Using claims data to analyze these common factors I came to 
the same conclusion.   
 The odds ratio calculation is the main factor I used to quantify how strongly my 
independent variables are associated with my dependent variable.  The odds ratio is calculated by 
dividing the probability of the dependent variable being 1 by 1 minus the probability of the 
dependent variable being 1.   
 
In my analysis each odds ratio is calculated by dividing the probably of the patient having a kidney 
transplant based on each specific risk factor.  By looking at the odds ratio estimates provided with 
my final output in Table 3 it shows that a person with end stage renal disease is 1.854 times more 
like to receive a kidney transplant than someone without a claims diagnosis of end stage renal 
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disease.  Logically, this makes sense and is supported by other research and data.  When a patient 
develops end stage renal disease a kidney transplant is likely the only option so I would expect the 
odds ratio on this estimate to be high.  Similarly, diabetes is also a leading cause of kidney 
transplantation and an odds ratio of 1.29 indicates the patient is 1.29 times more likely to receive 
a kidney transplant than someone without this diagnosis.  Interestingly, the diagnosis of 
hypertension with chronic kidney disease has a relatively low odds ratio only indicating a patient 
with this diagnosis as having an increased likelihood of kidney transplantation of 1.092 times that 
of someone without that diagnosis.  This low odds ratio could be due to the diagnosis being very 
specific and some of the variation could be picked up by the chronic kidney disease diagnosis.   
 The final model seems to have a very good fit compared to an empty model.  As shown by 
the Model Fit Statistics computed by my SAS program (Table 3) the three criteria used to 
determine overall fit all have very high Chi-Square estimates and low P values.  This would seem to 
indicate the variables I chose to include in my final model are reasonable and I should not reject 
my model.   
Even though my final model has a limited number of independent variables, it does a 
relatively good job of predicting kidney transplantation based on the seven risk factors included.  
Of these seven risk factors, the diagnosis of end stage renal disease has the most impact on 
predicting if a patient will need a kidney transplant in the future.  By looking at all the variables as 
a whole, a researcher could use the corresponding odds ratios of all of these variables and predict 
which patients will eventually need a kidney transplant with relative confidence.  As stated earlier, 
using claims data alone could lead to some false positives based on errors in claims data and the 
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fact that claims data may not tell the whole story.  Even with these limitations, my analysis could 



















Overall, claims data paints a good picture of each patient’s overall health and has proven 
to be very useful when looking for risk factors leading to kidney transplant.  In terms of data to 
include in a model I think the data I am lacking most is clinical data.  Data such as test results from 
blood or urine samples, blood pressure, and heart rate would provide even more insight into the 
patient’s health.  Although this information would be nice to have, a lot of what is in the claims 
data can help explain the outcome of some test results.  For example, the results of a GFR test 
would indicate what stage of renal failure a patient is in.  In this case using the diagnosis code to 
show what stage of renal failure a patient is in can be just as useful as the clinical data.   
In this analysis I am only looking at the Medicare population for a limited time period of 
four years.   This population only includes older patients so I’m not looking at the entire 
population as a whole.  Most people needing kidney transplants are older so this shouldn’t’ have a 
large impact on the results, but it should be noted that I’m not looking at all ages and groups of 
people.  Using claims data older than four years old would also be useful in this analysis to 
potentially identify kidney transplant recipients earlier.  Chronic kidney disease can develop over a 
long period of time and there could be some diagnoses very early in the patient’s care that may be 
useful in predicting future kidney transplant recipients.   
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Based on the results of this model it would be interesting to put this method into practice 
and attempt to predict future kidney transplant recipients in a health plan.  The health plan 
researcher could then follow the patients who were flagged as potentially needing a kidney 
transplant and see which ones did in fact require a kidney transplant in the future.  This could be a 
very long process since developing end stage renal disease can take many years but it would be a 
















 Kidney transplantation is a costly and life altering procedure that can potential decrease a 
patient’s quality of life.  It is important to identify potential kidney failure as early as possible to 
help increase positive outcomes for the patient and to help reduce costs associated with end stage 
renal disease.  By identifying a patient early it is possible to be put on a kidney donor waiting list 
earlier to potentially decrease the time waiting for a kidney while the person is on dialysis.  The 
longer a patient is on dialysis the higher risk they will have of developing complications related to 
kidney failure.  They can also expect a decreased life expectancy after the transplant.   
 My analysis confirms what prior clinical research has shown except I am using claims data 
in place of clinical data.  Major risk factors cited in prior research include diabetes, hypertension, 
and end stage renal disease and I also show similar results.  Based on these results it may be 
possible to predict other potential health outcomes using claims data in place of other research 
methods.  This may provide useful information to health insurance companies and others who do 
not have direct access to clinical data.   
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